Executive Summary
Apple’s IPR against Omni MedSci’s wearable physiological measurement patent resulted in all challenged claims being held unpatentable. The Board found the claims obvious over Lisogurski, Carlson, and Mannheimer under §103(a).
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in SAMSUNG ELECTRONICS CO., LTD. et al. vs OMNI MEDSCI, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Inari Agriculture, Inc.vsPioneer Hi-Bred International, Inc.
The USPTO Director denied Inari Agriculture's request to review the PTAB's denial of institution for Pioneer Hi‑Bred's seed‑technology patent, leaving the denial in place.
MediaTek Inc.vsDAEDALUS PRIME LLC
MediaTek has filed an IPR petition challenging all 24 claims of Daedalus Prime’s ’838 patent covering a hardware security engine for secure communications. The petition argues obviousness based on prior art combinations and seeks institution of the review.
Reolink Innovation Inc. et al.vsTHROUGH TEK TECHNOLOGY (SHENZHEN) CO., LTD. et al.
The PTAB granted institution of IPR for Reolink Innovation Inc., finding a reasonable likelihood of prevailing on obviousness grounds (35 U.S.C. § 103). The challenge targets core P2P networking and video streaming claims against THROUGHTEK CO., LTD.'s patent.
Samsung Electronics Co., Ltd. et al.vsNetlist, Inc.
The PTAB denied institution for IPR2025-01402 because the petitioner failed to show a reasonable likelihood of prevailing on any challenged claims. The decision was based on a merits review under 35 U.S.C. § 314(a).
MOTOROLA SOLUTIONS, INC. et al.vsStellar, LLC
The Director granted review of an institution decision and subsequently denied the IPR for Motorola Solutions against Stellar, LLC. The denial was based on Fintiv factors favoring dismissal due to extensive prior litigation in district court.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.